Benzinga -
- Cellectis S.A (NASDAQ: CLLS) highlighted updated clinical data on its Phase 1/2a BALLI-01 trial (evaluating UCART22) and on its Phase 1 AMELI-01 trial (evaluating UCART123).
- Compared to the last clinical update on BALLI-01 at ASH 2021, the presented data comes from five additional patients who received UCART22 at dose level 3 (DL3) 5x106 cells/kg after lymphodepletion with FCA.
- Evidence of UCART22 anti-tumor activity was observed in 60% (n=3) of the five patients.
- A patient experienced a durable, minimal residual disease (MRD) negative complete response with incomplete count recovery (CRi) that continues beyond six months.
- The company also shared preliminary data from patients who received UCART123.
- The FCA LD regimen resulted in robust lymphodepletion for greater than 28 days in all patients. Seven out of nine patients demonstrated UCART123 expansion.
- Two out of eight patients (25%) at DL2 with the FCA arm achieved a meaningful response.
- A patient with stable disease achieved greater than 90% bone marrow blast reduction (60% to 5%) at Day 28.
- Price Action: CLLS shares are up 8.52% at $2.42 on the last check Tuesday.
- Photo Via Company